



Orkambi (lumacaftor/Ivacaftor) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA. **URGENT**

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page





Orkambi (lumacaftor/Ivacaftor) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Cystic fibrosis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Will drug be used as part of a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No Is this request for initial therapy (meaning the patient has not received therapy with Orkambi in the past AND there are no paid claims for Orkambi in member's history)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>If No, please complete "Renewal Therapy" section below.</i> Does the patient have the F508 deletion mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Test documentation must be provided.</i> <u>If patient is under the age of 6 years, please answer the following:</u> Does patient have documentation of compromised lung function with at least one of the following: <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation must be provided.</i> <input type="checkbox"/> Infant Pulmonary Function Test(IPFT) <input type="checkbox"/> Number of or history of cystic fibrosis(CF) exacerbations requiring antibiotics either outpatient or inpatient <input type="checkbox"/> CT evidence of persistent bronchiectasis <u>If patient is 6 years of age or older, please answer the following:</u> Is documentation available showing this patient's most recent (baseline) FVC measurement, obtained within the past 30 days, to be greater than or equal to 40% predicted?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit this documentation, such as chart notes.</i> Is documentation available showing this patient's most recent (baseline) measurements for FEV1 and FEV1 percentage of predicted, obtained within the past 30 days while the patient is NOT receiving treatment with Orkambi?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit this documentation, such as chart notes.</i>		
Reauthorization: You must answer ALL of the following questions: Is this request for renewal of therapy (meaning the patient is currently receiving therapy AND paid claims are in member's history)? <input type="checkbox"/> Yes <input type="checkbox"/> No		





Orkambi (lumacaftor/Ivacaftor) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Note: use of samples only and/or access through patient assistance program only does not qualify as current therapy subject to renewal; those should be submitted as initial therapy instead.

If No, please complete "Initial Therapy" section above.

Has patient had a lung transplant? Yes No

For patients under 6 years of age, please answer the following:

Does patient have a disease response as indicated by one or more of the following: Yes No *Please submit this documentation, e.g., chart notes*

- Decreased pulmonary exacerbations compared to pre-treatment baseline
- Decrease in decline of lung function as measured by percent predicted FEV1 from date of start of Orkambi(lumacaftor/ivacaftor)
- Improvement in quality of life demonstrated by at least 2 of the following:
 - Cystic Fibrosis Questionnaire-Revised Score(CFQ-R)
 - Weight gain
 - Increase in height.

For patients 6 years of age or older, please answer the following:

Is documentation available which shows the patient's current FEV1 measurements?* Yes No
**Please submit this documentation, such as chart notes of the most recent FEV1 and FEV1 percentage of predicted measured within the previous 30 days while the patient is receiving treatment with Orkambi.*

Is the patient's current FEV1 percentage of predicted increased by at least 2.6 absolute percentage points greater than the baseline FEV1 percentage of predicted?* Yes No

**Please submit this documentation, such as chart notes. Baseline FEV1 percentage of predicted is defined as the most recent FEV1 percentage of predicted that was measured while the patient is not receiving treatment with Orkambi.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: _____





**Orkambi (lumacaftor/Ivacaftor)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management, LLC

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811

